Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.
HI-Bio has raised $95.0M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
HI-Bio's investors include ARCH Venture Partners, Alpha Wave Global, Jeito Capital, Viking Global Investors, Arkin Holdings.
HI-Bio is headquartered in South San Francisco, United States.
Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.
HI-Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HI-Bio — Funding & Investors." VCBacked, January 4, 2024, https://www.vcbacked.co/company/hi-bio. Accessed July 20, 2026.
VCBacked. (2024). HI-Bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/hi-bio
{{cite web |title=HI-Bio — Funding & Investors |url=https://www.vcbacked.co/company/hi-bio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated